Last checked at 7 Aug 2020 10:00
7th August 2020
Hikma Finance USA LLC
Post Stabilisation Notice
HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
Issuer: | Hikma Finance USA LLC |
Guarantor (if any): | Hikma Pharmaceuticals plc, Al Jazeerah Pharmaceutical Industries Ltd., Arab Pharmaceutical Manufacturing PSC, Eurohealth, (U.S.A.) Inc., Hikma Farmacêutica (Portugal) S.A., Hikma Injectables USA Inc., Hikma Labs Inc., Hikma Pharma S.A.E., Hikma Pharmaceuticals International Limited, Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals USA Inc., Hikma Specialty USA Inc. and West-Ward Columbus Inc. |
Aggregate nominal amount: | USD 500,000,000 |
Description: | 3.25% due 9th July 2025 |
Offer price: | 98.862 |
Stabilising Managers: | BofA Securities, Citi, HSBC, Mizuho Securities |
This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction